

4-(cyclopropyloxy)-3-[(morpholin-4-ylacetyl)amino]-N-[5-(pyrazin-2-yl)-1,3,4-thiadiazol-2-yl]benzamide,

N-(3,3'-bipyridin-6-yl)-4-(cyclopropyloxy)-3-[(morpholin-4-ylacetyl)amino]benzamide, and

N-[5-(6-aminopyridin-3-yl)-1,3,4-thiadiazol-2-yl]-4-(cyclopropyloxy)-3-[(morpholin-4-ylacetyl)amino]benzamide,

or a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

9. A compound of general formula (I), or a stereoisomer, a tautomer, an N oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 8, for use in the treatment or prophylaxis of a disease.

10. A pharmaceutical composition comprising a compound of general formula (I), or a stereoisomer, a tautomer, an N oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 8, and a pharmaceutically acceptable diluent or carrier.

11. A pharmaceutical combination comprising :

- one or more first active ingredients selected from a compound of general formula (I) according to any of claims 1 to 8, and
- one or more second active ingredients selected from chemotherapeutic anti cancer agents.

~~12. Use of a compound of general formula (I), or a stereoisomer, a tautomer, an N oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 8, for the prophylaxis or treatment of a disease.~~

~~13~~12. Use of a compound of general formula (I), or a stereoisomer, a tautomer, an N oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 8, for the preparation in the manufacture of a medicament for the prophylaxis or treatment of a disease.

~~14~~13. Use according to claim 9, ~~12~~ or ~~13~~12, wherein said disease is a disease in which aberrant Wnt signalling is implicated in a patient.


~~15~~14. Use according to claim 9, ~~12, 13~~ or ~~14~~13, wherein the disease is a genetic disease caused by mutations in Wnt signaling components, wherein the genetic disease is chosen from: polyposis coli, osteoporosispseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Müllerian-duct regression and virilization, SERKAL

syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinz el
phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, splithand/foot malformation,
caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal
hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX)
5 syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-
Wiedemarm Syndrome and Rett syndrome.

1615. Use according to claim 9, 12, 13 or 1413, wherein the disease is a disease of uncontrolled cell
growth, proliferation and/or survival, an inappropriate cellular immune response, or an
inappropriate cellular inflammatory response, particularly in which the uncontrolled cell growth,
10 proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular
inflammatory response is mediated by the Wnt pathway, more particularly in which the disease of
uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or
inappropriate cellular inflammatory response is a haematological tumour, a solid tumour and/or
metastases thereof, e.g. leukaemias and myelodysplastic syndrome, malignant lymphomas, head and
15 neck tumours including brain tumours and brain metastases, tumours of the thorax including non
small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and
other gynaecological tumours, urological tumours including renal, bladder and prostate tumours,
skin tumours, and sarcomas, and/or metastases thereof.

1716. Use of

20 an intermediate compound of general formula (VI):



(VI)

in which R², R³, R⁵, and R⁶ are as defined for general formula (I) in any one of claims 1 to 8,
or


25 an intermediate compound of general formula (XI):

and X represents a group enabling palladium catalysed coupling reactions, such as chloro, bromo, iodo, trifluoromethylsulfonyloxy, nonafluorobutylsulfonyloxy or a boronic acid or an ester thereof,

for the preparation of a compound of general formula (I) according to any one of claims 1 to 8.

5

1817. An intermediate compound of general formula (VI):




(VI)

in which R^2 , R^3 , R^5 , and R^6 are as defined for general formula (I) in any one of claims 1 to 8,

10

or

an intermediate compound of general formula (XVII):



(XVII)

15 in which R^2 , R^3 , R^5 , and R^6 are as defined for general formula (I) in any one of claims 1 to 8,

or

an intermediate compound of general formula (XXIV):